# Mendelian Randomization analysis to provide support for causal associations on frailty 

LUND UNIVERSITY POPULATION RESEARCH PLATFORM (LUPOP) SEMINAR SERIES<br>March 17, 2022

Sara Hägg
Docent in Molecular Epidemiology
Department of Medical Epidemiology and Biostatistics (MEB)
Karolinska Institutet

## Outline

- Introduction to Mendelian Randomization
- Assumptions of Mendelian Randomization
- Introduction to frailty
- Example studies using MR and frailty


## Mendelian Randomization \& RCT



## Traditional epidemiology designs

- Observational studies are subject to confounding, selection bias and reverse causation



## Mendelian randomization design

- Take the advantage of genetic variants as a nonconfounded proxy for the risk factor



## Mendelian randomization: example

The enzyme aldehyde dehydrogenase is responsible for efficient metabolism of alcohol after it has been oxidized to acetaldehyde. Peak blood acetaldehyde concentrations after drinking alcohol are 18 times higher among people who are homozygous for the null variant allele and five times higher among heterozygous people compared with people with two functioning alleles.


## Core assumptions of MR

- An instrumental variable $(\mathrm{G})$ should satisfy the following assumptions:

1. The IV $G$ is robustly associated with the exposure of interest $X$
2. $G$ is independent of confounding factors $U$ that confound the association of $X$ and the outcome $Y$
3. $G$ is independent of outcome $Y$ given $X$ and confounding factors $U$ (no pleiotropy)


## What data can be used?

## One-sample



- Exposure and outcome in the same data
- Meta-analyses, e.g., consortium
- Individual level data, e.g., UK Biobank


## Two-sample



- Exposure and outcome in different data
- Summary level data, e.g., consortium
- An instrumental variable (G) should satisfy the following assumptions:

Table 1 | Three key assumptions that must hold for a Mendelian randomisation study to be valid

|  |  | Tools to assess plausibility |  |
| :--- | :--- | :--- | :--- |
| Assumption | Description | Single sample | Two sample |
| Relevance <br> assumption | The genetic variants associate with the <br> risk factor of interest | The partial F statistic and partial $r$ <br> squared, or risk difference | Variants are associated with the risk factor in a large ge- <br> nome-wide study |

Neil M Davies et al. BMJ 2018;362:bmj.k601

$\mathbf{S N P}_{\text {ALDH }}{ }^{2}$

## smoking



## Assumption 1: SNP $(\mathrm{G})$ is robustly associated with exposure ( X )

Genetic variants of telomere length


## Testing assumption 1: FTO vs. SCORE



$$
\begin{aligned}
& \mathrm{n}=124,527 \\
& P \text {-value }=9 \times 10^{-44}
\end{aligned}
$$

SCORE_BMI, AGEPOOLED POOLED
filename
b58c
egcutmetabo
egcutomn
fro2
fron
fras

- An instrumental variable $(G)$ should satisfy the following assumptions:


## Karolinska

 Institutet1. The IV $G$ is robustly associated with the exposure of interest $X$
2. $G$ is independent of confounding factors $U$ that confound the association of $X$ and the

Table 1 | Three key assumptions that must hold for a Mendelian randomisation study to be valid

|  |  |  |  |
| :--- | :--- | :--- | :--- |
| Assumption | Tools to assess plausibility |  |  |
| Relevance Single sample Two sample <br> assumption   | The genetic variants associate with the <br> risk factor of interest | The partial F statistic and partial $r$ <br> squared, or risk difference | Variants are associated with the risk factor in a large ge- <br> nome-wide study |
| Independence <br> assumption | There are no unmeasured confounders <br> of the associations between genetic <br> variants and outcome | Covariate balance tests and bias <br> component plots. Adjusting for principal <br> components of population stratification | Evidence from large genome-wide association studies on the <br> association of the genetic variants used as instruments with <br> other baseline covariates |

Neil M Davies et al. BMJ 2018;362:bmj.k601

$\mathbf{S N P}_{\text {ALDH2 }}$ smoking

alcohol
CVD


The assignment of the paternal or maternal allele to a gamete is random
This implies that U cannot modify $G$

## Testing assumption 2

rs1205

Relation between ALDH2 genotype and various characteristics ${ }^{8}$

|  | Homozygous <br> for null variant | Heterozygous <br> for null variant | Homozygous for <br> functioning variant |
| :--- | :---: | :---: | :---: |
| Mean alcohol consumption (ml/day) | 5.3 | 15.1 | 29.2 |
| Mean age (years) | 61.3 | 61.5 | 60.6 |
| \% smokers | 48.5 | 47.9 | 47.7 |
| Mean HDL cholesterol concentration <br> (mmol/ $)$ | 1.24 | 1.35 | 1.4 |
| \% with hypertension | 40.6 | 37.7 | 46.9 |

## Variable

$\log$ C-reactive protein ( $\mathrm{mg} / \mathrm{I}$ )
Age at survey (yrs)
Body mass index (kg/m²)
Systolic BP $(\mathrm{mmHg})$
Diastolic BP (mm
Total cholesterol (mmol
Total cholesterol (mmol $)$
Non-HDL-C $(\mathrm{mmol} / \mathrm{l})$
Non-HDL-C (mm
HDL-C (mmol/I)
log Triglycerides (mmol/l)
LDL-C ( $\mathrm{mmol} / \mathrm{I}$ )
Apo A1 ( $\mathrm{g} / \mathrm{l}$ )
Apo B ( $g / l$ )
Albumin ( $\mathrm{g} / \mathrm{l}$ )
Lipoprotein(a) (mg/dl)
log Interleukin-6 (mg/l)
log interleukin-6 (mg $)$
Fibrinogen ( $\mu \mathrm{mol} / \mathrm{l}$ )
Fibrinogen ( $\mu \mathrm{mol} / \mathrm{l})$
log Leukocyte count ( $\times 10^{\wedge} 9 / 1$ )
log Leukocyte cou
Glucose (mmol/l)
Glucose (mmol
Smoking amount (pack yrs)
Weight (kg)
Height (cm)
Waist/Hip ratio

## Per allele effect

0.17 ( $0.15,0.19$ )
$0.00(-0.01,0.00)$ $0.00(-0.01,0.01)$ $0.00(-0.01,0.01)$ 0.01 ( $0.00,0.02$ ) $0.00(-0.01,0.01)$ $0.00(-0.01,0.00)$ $0.00(0.00,0.01)$ $0.00(-0.01,0.01)$ $0.00(-0.01,0.00)$ $0.01(0.00,0.02)$ $0.00(-0.01,0.01)$ $0.01(-0.02,0.03)$ 0.00 ( $-0.02,0.02$ ) 0.00 ( $-0.02,0.02$ ) $-0.01(-0.02,0.00)$ $-0.01(-0.03,0.01)$ 0.01 ( $0.00,0.02$ ) $-0.02(-0.06,0.01)$ $0.01(-0.01,0.02)$ $0.01(0.00,0.02)$ $0.01(0.00,0.02)$

- An instrumental variable (G) should satisfy the following assumptions:

1. The IV $G$ is robustly associated with the exposure of interest $X$
2. $G$ is independent of confounding factors $U$ that confound the association of $X$ and the outcome $Y$
3. $\quad G$ is independent of outcome $Y$ given $X$ and confounding factors $U$
(no pleiotropy)

Table 1 | Three key assumptions that must hold for a Mendelian randomisation study to be valid

|  |  | Tools to assess plausibility |  |
| :--- | :--- | :--- | :--- |
| Assumption | Description | Single sample | Two sample |
| Relevance <br> assumption | The genetic variants associate with the <br> risk factor of interest | The partial F statistic and partial r <br> squared, or risk difference | Variants are associated with the risk factor in a large ge- <br> nome-wide study |
| Independence <br> assumption | There are no unmeasured confounders <br> of the associations between genetic <br> variants and outcome | Covariate balance tests and bias <br> component plots. Adjusting for principal <br> components of population stratification | Evidence from large genome-wide association studies on the <br> association of the genetic variants used as instruments with <br> other baseline covariates |
| Exclusion <br> restriction | The genetic variants affect the outcome <br> only through their effect on the risk factor <br> of interest | Biological knowledge, tests of association <br> of the genetic variants and potential <br> alternative mediating pathways | Evidence from large genome-wide association studies that the <br> genetic variants associate with alternative pathways. MR Egger <br> test for pleiotropy, Cook's distance evaluation of outliers |

Neil M Davies et al. BMJ 2018;362:bmj.k601

$\mathrm{SNP}_{\text {ALDH2 }} \longrightarrow$ alcohol

## smoking



## Assumption 3: SNP (G) is independent of outcome (Y) if adjusted for X



Horizontal pleiotropy


Vertical pleiotropy

Testing assumption 3

"Analyses were conducted using the inverse variance-weighted, weighted median, MR-PRESSO, MR-Egger, and multivariable MR methods."

## What exactly is frailty?

- Conceptually defined as an "age-associated decline in physiological reserves and function across multiorgan systems making the individual vulnerable to adverse outcomes"
- Strongly predictive of mortality, falls, fractures, disability, hospitalizations, ER visits, morbidity...


Clinical Frailty Scale*

## How to measure frailty?

- ~30 different scales
- Clinically most useful scales
> Clinical Frailty Scale (CFS)
> The FRAIL scale
$>$ Fried phenotypic model

1 Very Fit - People who are robust, active, energetic and motivated. These people commonly exercise regularly. They are among the fittest for their age, 2 Well - People who have no active disease symptoms but are less fit than category 1 . Often, they exercise or are very active occasionally, e.g. seasonally.

$\theta$3 Managing Well - People whose medical problems are well controlled, but are not regularly active beyond routine walking.

4 Vulnerable - While not dependent on others for daily help, often symptoms limit activities. A common complaint is being "slowed up", and/or being tired during the day

5 Mildly Frail - These people often have more A evident slowing, and need help in high order IADLs

- (finances, transportation, heavy housework, medications). Typically, mild frailty progressively impairs shopping and walking outside alone, meal preparation and housework.
f 6 Moderately Frail - People need help with all outside activities and with keeping house. Inside, they often have problems with stairs and need help with bathing and might need minimal assistance (cuing, standby) with dressing

7 Severely Frail - Completely dependent for personal care, from whatever cause (physical or cognitive). Even so, they seem stable and not at high risk of dying (within $\sim 6$ months).

8 Very Severely Frail - Completely dependent, approaching the end of life. Typically, they could not recover even from a minor iliness.

$\stackrel{\theta}{2}$9 Terminally III - Approaching the end of life. This category applies to people with a life expectancy <6 months, who are not otherwise evidently frail.

## Scoring frailty in people with dementia

The degree of frailty corresponds to the degree of dementia Common symptoms in mild dementia include forgetting the details of a recent event, though still remembering the event itself, repeating the same question/story and social withdrawal.
In moderate dementia, recent memory is very impaired, even though they seemingly can remember their past life events well. They can do personal care with prompting.

In severe dementia, they cannot do personal care without help.

- 1. Canadian Study on Health \& Aging, Revised 2008. 2. K. Rockwood et al. A global clinical measure of fitness and frailty in elderly people. CMAJ 2005;173:489-495.
- Most common definitions for research purposes

Fried phenotypic model (2001)
> Rockwood Frailty Index, deficit accumulation model (2002)

## Fried phenotypic model (FP)

Weight loss Unintentional loss of $\geq 4.5 \mathrm{~kg}$ in the past year
Weakness Hand-grip strength in the lowest 20\% quintile adjusted for sex and body mass index
Exhaustion Poor endurance and energy, self-reported from the Center for Epidemiologic Studies Depression Scale

Slowness Walking speed under the lowest quintile adjusted for sex and height
Low physical Lowest quintile of kilocalories of physical activity activity level during the past week, measured by the Minnesota Leisure Activity Scale

Score across the five items:
0=non-frail
1-2=pre-frail $\geq 3$ = frail

Fried et al. 2001. J Gerontol 56 (3): M146-56

## Frailty Index (FI)

- Measures the accumulation of deficits: signs, symptoms, diseases, difficulties in functioning, psychosocial well-being etc.
- FI = number of health deficits present/number of health deficits measured
- For example, a person with 8 of 40 deficits considered has an FI of $8 / 40=0.2$
- Robust and replicative across different cohorts when different items and different numbers of items are used

|  | Item | Scoring |
| :---: | :---: | :---: |
| ample ite | Hearing status | Perfect=0, Good=0.25, Pretty Good=0.5, Bad=0.75, Deaf or almost deaf=1 |
|  | Vision status | Perfect=0, Good=0.25, Pretty Good=0.5, Bad=0.75, Blind or almost blind=1 |
|  | Health prevents from doing things normally would like to do | No=0, Somewhat=0.5, Yes=1 |
|  | Self-reported general health | Good=0, Mediocre=0.5, Bad=1 |
|  | Cancer or leukemia | No=0, Yes=1 |
|  | Rheumatoid arthritis | No=0, Yes=1 |
|  | Arthritis | No=0, Yes=1 |
|  | Chronic bronchitis or emphysema | No=0, Yes=1 |
|  | Cataracts | No=0, Yes=1 |
|  | Chest pain | No=0, Yes=1 |
|  | Circulation problems in arms or legs | No=0, Yes=1 |
|  | Persistent cough | No=0, Yes=1 |
|  | Diabetes | No=0, Yes=1 |
|  | Dizziness | No=0, Yes=1 |
|  | Gastric ulcer | No=0, Yes=1 |
|  | Allergies/allergic manifestations | No=0, Yes=1 |
|  | Asthma | No=0, Yes=1 |
|  | Shower and bathe | No problem=0, Needs help=0.5, Cannot=1 |
|  | Get in and out of bed | No problem $=0$, Needs help $=0.5$, Cannot=1 |
|  | Dress and undress | No problem=0, Needs help=0.5, Cannot=1 |
|  | Self-grooming | No problem=0, Needs help=0.5, Cannot=1 |
|  | Walking | No problem=0, Needs help $=0.5$, Cannot=1 |
|  | Trouble getting to toilet in time | No=0, Yes=1 |
|  | Manage money | No problems=0, Needs help=0.5, Doesn't do=1 |
|  | Feeling lonely | Never, almost never, rather seldom=0 Quite often, always, almost always=1 |
|  | Consider oneself happy and carefree | No=1, Yes=0 |
|  | Usually feels tired | No=0, Yes=1 |

## FI predicts mortality

UK biobank



Swedish Twin Registry

- Single responders
- DZ twin pairs
- MZ twin pairs


CVD FI 0.095 -.......... Cementia FI 0.080
Survivors FI 0.048

## Swedish Adoption/Twin

Study of Aging (SATSA)
Williams et al. J Gerontol, 2018
Li et al, BMC Med, 2019
Jiang et al. Aging, 2017


Other FI 0.107 ----- Dementia FI 0.065
CVD FI 0.131 -........ Cancer FI 0.089

## Genetic variation and FI

A genome-wide association study of the frailty index highlights brain pathways in ageing

```
Janice L. Atkins \({ }^{1} \odot\) | Juulia Jyhhävä \({ }^{2}\) | Nancy L. Pedersen \({ }^{2,3}\) | Patrik K. Magnusson \({ }^{2}\) |
Yi Lu \({ }^{2} \mid\) Yunzhang Wang \({ }^{2} \mid\) Sara Hägg \(^{2}\) | | David Melzer \({ }^{1,4} \mid\) Dylan M. Williams \({ }^{2,5}\) |
```

Luke C. Pilling ${ }^{1,4} \oplus$


Meta-analysis GWAS of Frailty Index (normalized) in 164,610 UK Biobank participants aged 60-70 of European descent and 10,616 TwinGene participants aged 4187 years.

## Mendelian Randomization: education and FI

## PMC full text:

Aging Cell. 2021 Sep: $20(9)$ ) e13459
Published online 2021 Aug 25. doi: 10.1111/acel. 13459
Copyright/License Request permission to reuse
FIGURE 3


# SNPs $\longrightarrow$ education $\longrightarrow$ FI 

On average, a standard deviation increase (i.e. an additional 3.7 years) in education was predicted to lead to $13.6 \%$ lower frailty by the seventh decade of life in UK Biobank participants.

[^0]
## Frailty \& nutrition

- Frail individuals are often malnourished
- Frailty is associated with sarcopenia
- Interventions include nutrient supplementations with high protein and energy intake
- RCTs use mixed interventions or are missing


Karolinska Institutet

## Protein Nutritional Status and Frailty: A Mendelian Randomization Study

Yasutake Tomata, ${ }^{1,2}$ Yunzhang Wang, ${ }^{1}$ Sara Hägg, ${ }^{1}$ and Juulia Jylhävä ${ }^{1,3}$


FIGURE 1 Association between genetically predicted serum albu$\min (\mathrm{g} / \mathrm{L})$ concentrations and frailty index in women ( $n=189,949$ ): a result of the MR-Egger method

TABLE 2 MR results of the serum albumin and frailty index by using UK Biobank data ${ }^{1}$

| MR method | $\beta$ | $(95 \% \mathrm{Cl})$ | $P$ value |
| :--- | ---: | :---: | :---: |
| All $(n=356,432)^{2}$ |  |  |  |
| IVW | -0.023 | $(-0.141,0.094)$ | 0.694 |
| Penalized IVW | -0.120 | $(-0.255,0.016)$ | 0.083 |
| Weighted median | -0.030 | $(-0.189,0.129)$ | 0.712 |
| MR-Egger | -0.015 | $(-0.330,0.299)$ | 0.923 |
| MR-Egger (intercept) | -0.001 |  | 0.957 |
| Women ( $n=189,949)^{2}$ |  |  |  |
| IVW | -0.172 | $(-0.336,-0.007)$ | 0.041 |
| Penalized IVW | -0.296 | $(-0.477,-0.114)$ | 0.001 |
| Weighted median | -0.185 | $(-0.420,0.050)$ | 0.122 |
| MR-Egger | -0.286 | $(-0.691,0.120)$ | 0.167 |
| MR-Egger (intercept) | 0.020 |  | 0.546 |
| Men (n=166,483) |  |  |  |
| IVW | 0.123 | $(-0.041,0.287)$ | 0.141 |
| Penalized IVW | 0.123 | $(-0.041,0.287)$ | 0.141 |
| Weighted median | 0.150 | $(-0.050,0.349)$ | 0.141 |
| MR-Egger | 0.217 | $(-0.232,0.667)$ | 0.343 |
| MR-Egger (intercept) | -0.017 |  | 0.659 |

${ }^{1} \beta$, coefficient of serum albumin (g/L); IVW, inverse variance weighted method; MR, Mendelian randomization.
${ }^{2}$ Number of participants who were included in the analysis for summary statistics of frailty index.

## Article

## Fatty Acids and Frailty: A Mendelian Randomization Study

Yasutake Tomata ${ }^{1,2, *}$, Yunzhang Wang ${ }^{1}$, Sara Hägg ${ }^{1}$ and Juulia Jylhävä ${ }^{1,3}$ ©

Table 3. MR results of the fatty acids and frailty index.

|  | MR |  |  | Multivariate MR ${ }^{\text {a }}$ |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | $\beta$ | (95\%CI) | $p$ | $\beta$ | (95\%CI) | $p$ |
| Non-PUFAs |  |  |  |  |  |  |
| Saturated fatty acids |  |  |  |  |  |  |
| Palmitic acid (16:0) | -0.063 | $(-0.255,0.129)$ | 0.518 | 0.288 | (0.128, 0.447) | <0.001 |
| Stearic acid (18:0) | 0.178 | (0.050, 0.307) | 0.007 | 0.361 | (0.155, 0.567) | 0.001 |
| Mono-unsaturated fatty acids |  |  |  |  |  |  |
| Palmitoleic acid (16:1n-7) | -1.127 | (-1.868, -0.387) | 0.003 | 0.026 | ( $-1.083,1.135$ ) | 0.963 |
| Oleic acid (18:1n-9) | -0.304 | ( $-0.458,-0.150$ ) | <0.001 | -0.086 | ( $-0.330,0.158$ ) | 0.488 |
| PUFAs |  |  |  |  |  |  |
| n-6 PUFAs |  |  |  |  |  |  |
| Linoleic acid (18:2n6) | -0.039 | ( $-0.063,-0.016$ ) | 0.001 | 1.075 | $(-1.549,3.698)$ | 0.422 |
| Arachidonic acid (20:4n6) | 0.039 | (0.018, 0.060) | <0.001 | -0.266 | ( $-0.937,0.406$ ) | 0.438 |
| n-3 PUFAs |  |  |  |  |  |  |
| $\alpha$-Linolenic acid (18:3n3) | -4.379 | (-6.615, -2.143) | <0.001 | -44.36 | (-186.03, 97.32) | 0.539 |
| Eicosapentaenoic acid (20:5n3) | 0.722 | (0.323, 1.122) | <0.001 | -7.865 | $(-50.28,34.55)$ | 0.716 |
| Docosapentaenoic acid (22:5n3) | 0.849 | (0.442, 1.255) | $<0.001$ | 23.09 | $(-51.07,97.25)$ | 0.542 |
| Docosahexaenoic acid (22:6n3) | -0.088 | ( $-0.390,0.215$ ) | 0.571 | 4.482 | ( $-5.569,14.533$ ) | 0.382 |

Abbreviations: $\mathrm{MR}=$ Mendelian randomization with inverse variance weighted method using a fixed-effect model; $95 \% \mathrm{CI}=95 \%$ confidence interval; Multivariate MR = Multivariable Mendelian randomization. PUFA = polyunsaturated fatty acids. ${ }^{a}$ Multivariate model for non-PUFAs included palmitic acid, stearic acid, palmitoleic acid, and oleic acid as exposure variables. Multivariate model for PUFAs included linoleic acid, arachidonic acid, $\alpha$-Linolenic acid, eicosapentaenoic acid, docosapentaenoic acid, and docosahexaenoic acid as exposure variables.

## MR for estimating the causal effect of drug repurposing on age-related traits

Statins: HMG-CoA reductase inhibitors

| - cmas Catag | Emb |  |
| :---: | :---: | :---: |
| Gomememamon |  | $\mathrm{G} \longrightarrow \mathrm{HMGCR} \longrightarrow \mathrm{LDL} \longrightarrow \mathrm{Y}$ |
| amamemo | musar |  |
| Lomenere |  |  |
| Cytogenetic region © |  |  |
| Reposestatas 0 | Seme |  |
|  |  |  |
|  | : Linembemp |  |
|  | : |  |

## Is lifelong lowering of LDL cholesterol protective for the frailty index?

## SNP $\longrightarrow$ HMGCR $\longrightarrow$ LDL $\longrightarrow$ FI

Objective: Investigate association between LDL-lowering genetic variants and the frailty index (FI) in the UK Biobank using MR.

| GRS (number of SNPs) | Mechanism/drug |
| :---: | :---: |
|  |  |
| Large (274) | All GWAS hits for LDL |
| Small (50) | Remove pleiotropic SNPs |
| stach (16) | statins |
| PCSK9 (34) | alirocumab, evolocumab |
| ezetimibe |  |
| APCOB (30) | mipomersen |
| APOC3 (19) | Apolipoprotein C3 |
| LDLR (30) | LDL receptor |

Genetically-predicted life-long lowering of low-density lipoprotein cholesterol is associated with decreased frailty: A Mendelian randomization study in UK biobank




The Strategic Research Area in Epidemiology (SfoEpi) at KI KI-NIH joint doctoral program
KI Foundations
KI-China Scholarship Council

The Swedish Research Council
The National Institute on Aging (NIA/NIH)
The Swedish Cancer Society
King Gustaf V \& Queen Victoria Foundation of Freemason

## Thank you!

Aging Epidemiology research group at MEB

| Nancy Pedersen | Adil Supiyev |
| :--- | :--- |
| Juulia Jylhävä | Jonathan Mak |
| Kristina Johnell | Maté Szilcz |
| Karolina Kauppi | Jonas Wastesson |
| Yunzhang Wang | KK Kang |
| Xia Li | Qi Wang |
| Ida Karlsson | Xueying Qin |
| Ge Bai | Laura Kananen |
| Bowen Tang | Peggy Ler |
| Chenxi Qin | Pierre-Olivier Blotiere |
| Thaís Lopes de Oliveira | Géric Maura |
| Malin Ericsson | Yasutake Tomata |



Malin Ericsson
Yasutake Tomata


[^0]:    Mendelian randomization estimates for the effect of educational attainment on the frailty index in UK Biobank Points and error bars represent beta estimates and $95 \%$ confidence intervals for each
    SNP-education / SNP-FI association. The trend lines represent different methods for summarizing the estimates from individual SNPS-inverse variance weighting (IVW), weighted median and MR-Egger. The weighted median and MR-Egger estimates are less prone to bias from pleiotropy among the set of variants than IVW, given alternative assumptions hold. The MR-Egger method includes a test of whether the trend's intercept differs from zero, which indicates whether there is an overall imbalance (directional) of pleiotropic effects: such bias was not identified in this ducation-FI model

